Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway

Oncogene. 2000 Mar 23;19(13):1665-75. doi: 10.1038/sj.onc.1203452.

Abstract

Overexpression of epidermal growth factor receptor (EGFR) and establishment of transforming growth factor alpha (TGF alpha)/EGF autocrine system are frequently detected in tumor cells. In addition to mitogenic ability, we demonstrate in this report that EGF protects a human esophageal carcinoma (CE) cell line, CE81T/VGH, from staurosporine-induced apoptosis. The anti-apoptotic signal of EGF is alleviated by a MEK inhibitor PD98059 or an ERK2 dominant negative mutant but not by a phosphatidylinositol-3'-kinase (PI-3K) inhibitor wortmannin. Furthermore, v-raf blocks apoptosis induced by staurosporine. This evidence implies that the survival signal of EGF is mediated via the Raf-MEK-ERK pathway but not the PI3-K pathway. The survival effect of EGF is coincident with the induction of mcl-1, an antiapoptotic gene in the bcl-2 family. PD98059 also suppresses the induction of Mcl-1 by EGF, implying that EGF may up-regulate Mcl-1 via the MAP kinase pathway. Overexpression of mcl-1 is sufficient to protect against apoptosis, while transfection of a mcl-1 antisense plasmid causes cell death. The expression of mcl-1 antisense plasmid also suppresses the anti-apoptotic effect of EGF. Taken together, these results indicate that EGF may up-regulate Mcl-1 through the MAP kinase pathway to suppress apoptosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Androstadienes / pharmacology
  • Apoptosis / drug effects*
  • Apoptosis / genetics
  • Carcinoma / genetics
  • Carcinoma / pathology
  • Cysteine Endopeptidases / physiology*
  • Cysteine Proteinase Inhibitors / pharmacology*
  • DNA, Antisense / genetics
  • Epidermal Growth Factor / pharmacology*
  • ErbB Receptors / drug effects
  • ErbB Receptors / physiology*
  • Esophageal Neoplasms / genetics
  • Esophageal Neoplasms / pathology
  • Flavonoids / pharmacology
  • Gene Expression Regulation, Neoplastic / drug effects*
  • Humans
  • MAP Kinase Kinase Kinase 1*
  • MAP Kinase Signaling System / drug effects*
  • Mitogen-Activated Protein Kinase 1 / genetics
  • Mitogen-Activated Protein Kinase 1 / physiology
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases / physiology
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Neoplasm Proteins / biosynthesis*
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / physiology*
  • Phosphoinositide-3 Kinase Inhibitors
  • Protein Serine-Threonine Kinases / physiology
  • Proto-Oncogene Proteins c-bcl-2*
  • Proto-Oncogene Proteins c-raf / physiology
  • Recombinant Fusion Proteins / physiology
  • Staurosporine / antagonists & inhibitors*
  • Transfection
  • Tumor Cells, Cultured / drug effects
  • Wortmannin

Substances

  • Androstadienes
  • Cysteine Proteinase Inhibitors
  • DNA, Antisense
  • Flavonoids
  • Myeloid Cell Leukemia Sequence 1 Protein
  • Neoplasm Proteins
  • Phosphoinositide-3 Kinase Inhibitors
  • Proto-Oncogene Proteins c-bcl-2
  • Recombinant Fusion Proteins
  • Epidermal Growth Factor
  • ErbB Receptors
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-raf
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase Kinase 1
  • MAP3K1 protein, human
  • Cysteine Endopeptidases
  • Staurosporine
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • Wortmannin